Literature DB >> 31268978

Endogenous Gastrin Collaborates With Mutant KRAS in Pancreatic Carcinogenesis.

Sandeep Nadella1, Julian Burks1, Matthew Huber1, Juan Wang1, Hong Cao1, Bhaskar Kallakury2, Robin D Tucker2, Simina M Boca, Ashley Jermusyck3, Irene Collins3, Eveline E Vietsch4, Mariaelena Pierobon5, K Alex Hodge5, Waxing Cui6, Laufey T Amundadottir3, Emanuel Petricoin5, Narayan Shivapurkar1, Jill P Smith.   

Abstract

OBJECTIVE: The KRAS gene is the most frequently mutated gene in pancreatic cancer, and no successful anti-Ras therapy has been developed. Gastrin has been shown to stimulate pancreatic cancer in an autocrine fashion. We hypothesized that reactivation of the peptide gastrin collaborates with KRAS during pancreatic carcinogenesis.
METHODS: LSL-Kras; P48-Cre (KC) mutant KRAS transgenic mice were crossed with gastrin-KO (GKO) mice to develop GKO/KC mice. Pancreata were examined for 8 months for stage of pancreatic intraepithelial neoplasia lesions, inflammation, fibrosis, gastrin peptide, and microRNA expression. Pancreatic intraepithelial neoplasias from mice were collected by laser capture microdissection and subjected to reverse-phase protein microarray, for gastrin and protein kinases associated with signal transduction. Gastrin mRNA was measured by RNAseq in human pancreatic cancer tissues and compared to that in normal pancreas.
RESULTS: In the absence of gastrin, PanIN progression, inflammation, and fibrosis were significantly decreased and signal transduction was reversed to the canonical pathway with decreased KRAS. Gastrin re-expression in the PanINs was mediated by miR-27a. Gastrin mRNA expression was significantly increased in human pancreatic cancer samples compared to normal human pancreas controls.
CONCLUSIONS: This study supports the mitogenic role of gastrin in activation of KRAS during pancreatic carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31268978     DOI: 10.1097/MPA.0000000000001360

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  4 in total

1.  Vaccine against gastrin, a polyclonal antibody stimulator, decreases pancreatic cancer metastases.

Authors:  Nicholas Osborne; Rebecca Sundseth; Martha D Gay; Hong Cao; Robin D Tucker; Sandeep Nadella; Shangzi Wang; Xunxian Liu; Alexander Kroemer; Lynda Sutton; Allen Cato; Jill P Smith
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-08-21       Impact factor: 4.052

2.  Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model.

Authors:  Jill P Smith; Hong Cao; Wenqiang Chen; Bhaskar Kallakury; Teresa Phillips; Lynda Sutton; Allen Cato
Journal:  Cancer Prev Res (Phila)       Date:  2021-08-24

Review 3.  Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome.

Authors:  Lingaku Lee; Irene Ramos-Alvarez; Tetsuhide Ito; Robert T Jensen
Journal:  Int J Mol Sci       Date:  2019-10-16       Impact factor: 5.923

4.  Cholecystokinin-B Receptor-Targeted Nanoparticle for Imaging and Detection of Precancerous Lesions in the Pancreas.

Authors:  Jill P Smith; Hong Cao; Elijah F Edmondson; Siva Sai Krishna Dasa; Stephan T Stern
Journal:  Biomolecules       Date:  2021-11-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.